MAIA — MAIA Biotechnology, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1878313 ·
Last close
$1.18
Market Cap
$71.78M
52W High
$3.19
52W Low
$0.87
ADV30
565,379
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -8,110,078 | -7,943,587 | 28,240,171 | 27,595,831 | 7,565,161 |
| Mar 2026 | 0 | — | -6,736,364 | -6,369,652 | 35,322,645 | 34,413,110 | 7,559,877 |
| Dec 2025 | 0 | — | -3,955,922 | -3,628,762 | 9,704,656 | 8,658,031 | 7,328,793 |
| Sep 2025 | 0 | — | -9,360,926 | -8,903,189 | 11,782,021 | 10,891,736 | 11,740,351 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,953,652
Investing CF
—
Financing CF
$43,497,652
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.75
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-116,000,657
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-24,434,373
Pretax Income TTM
$-24,248,566
Interest Exp TTM
$-28
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,908,336 | -22,396,172 | 9,704,656 | 7,328,793 | 2,375,863 | -18,844,598 |
| Dec 2024 | 0 | -16,877,256 | -23,254,656 | 10,155,279 | 6,520,643 | 3,634,636 | -15,704,461 |
| Dec 2023 | 0 | -20,005,662 | -19,772,905 | 7,566,852 | 7,089,341 | 477,511 | -13,071,016 |
| Dec 2022 | 0 | -15,862,576 | -15,769,279 | 12,022,040 | 3,514,247 | 8,507,793 | -12,096,104 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.11
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FBIO | Fortress Biotech, Inc. | $72.37M | $2.17 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $72.70M | $1.36 | — |
| GOSS | Gossamer Bio, Inc. | $70.39M | $11.52 | — |
| CING | Cingulate Inc. | $70.09M | $4.82 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $69.98M | $1.16 | — |
News headlines (Yahoo Finance, 1h cache)
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
2026-09-23 13:17 · Yahoo
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
2026-09-22 12:47 · Yahoo
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
2026-09-16 12:15 · Yahoo
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
2026-09-15 12:15 · Yahoo
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
2026-09-10 12:15 · Yahoo
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
2026-08-17 12:00 · Yahoo
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
2026-06-25 12:08 · Yahoo
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
2026-06-18 12:30 · Yahoo
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
2026-06-10 13:15 · Yahoo
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
2026-06-04 13:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.